Acebilustat

Drug Profile

Acebilustat

Alternative Names: CTX-4430; EP-501

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Unknown
  • Developer Celtaxsys
  • Class Small molecules
  • Mechanism of Action Leukotriene A4 hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris; Cystic fibrosis
  • Phase I Hidradenitis suppurativa
  • Preclinical Rosacea

Most Recent Events

  • 09 Jan 2017 Phase-II clinical trials in Cystic fibrosis in Canada (PO) before January 2017
  • 01 Aug 2016 Celtaxsys completes phase II clinical trials in Acne vulgaris in Australia and New Zealand (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers, In adults) in Australia (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top